Match tier Likely match
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-16

Joshua Xu

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Researcher

Also affiliated: University of Sydney (2016–2022); United States Food and Drug Administration (2008–2025); University Health Network (2022); The University of Melbourne (2014); Duke University (2014); Fudan University (2022); Royal North Shore Hospital (2016–2022); Government of the United States of America (2021); Princess Margaret Cancer Centre (2022); Missouri Department of Agriculture (2024–2025); Regenxbio (United States) (2024); University of Michigan–Flint (2016); Cancer Research And Biostatistics (2024); Shanghai Institute of Measurement and Testing Technology (2023); Food and Drug Administration (2016–2024); State Key Laboratory of Genetic Engineering (2022); The Ohio State University (2013); ICF International (United States) (2008–2012); McMaster University (2021–2022)

Faculty Researcher

32 h-index 198 pubs 6,023 cited

  • Humans
  • High-Throughput Nucleotide Sequencing
  • Gene Expression Profiling
  • Artificial Intelligence
  • Drug Labeling
  • United States Food and Drug Administration
  • Animals
  • Sequence Analysis, RNA
  • Precision Medicine
  • United States
  • Neoplasms
  • Oligonucleotide Array Sequence Analysis
  • Polymorphism, Single Nucleotide
  • Quality Control
  • Algorithms

Biography and Research Information

OverviewAI-generated summary

Joshua Xu's research focuses on the analytical validity and quality control of high-throughput molecular profiling technologies, particularly in the context of precision medicine and toxicology. He has investigated methods for integrating multi-omics data, developing ratio-based quantitative profiling techniques and reference materials to improve the accuracy and reliability of transcriptomic and genomic data. His work addresses challenges such as batch effects in large-scale studies and the accurate resolution of structural variants for clinical diagnosis.

Xu has also explored the application of artificial intelligence and machine learning in predictive toxicology, examining the trade-offs between predictivity and explainability in models trained on datasets like Tox21. His research contributes to the development of verified genomic reference samples for assessing the performance of cancer panels and evaluating circulating tumor DNA sequencing assays for precision oncology.

With 198 publications and an h-index of 32, Xu is recognized as a highly cited researcher. His collaborations include numerous shared publications with researchers at the National Center for Toxicological Research, such as Leihong Wu, Weida Tong, and Binsheng Gong, as well as Donald J. Johann at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 32
  • Publications: 198
  • Citations: 6,023

Selected Publications

  • Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations (2025)
    npj Precision Oncology 5 citations DOI OpenAlex
  • Federated learning: a privacy-preserving approach to data-centric regulatory cooperation (2025)
    Frontiers in Drug Safety and Regulation 9 citations DOI OpenAlex
  • Zika and dengue viruses differentially modulate host mRNA processing factors defining its virulence (2025)
    NAR Molecular Medicine 1 citation DOI OpenAlex
  • Biomarkers of Neurotoxicity and Disease (2025)
    Elsevier eBooks 1 citation DOI OpenAlex
  • Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabel (2025)
    Drug Safety 15 citations DOI OpenAlex
  • Developing a Charlson Comorbidity Index for the American Indian Population Using the Epidemiologic Data from the Strong Heart Study (2024)
    Journal of Racial and Ethnic Health Disparities 1 citation DOI OpenAlex
  • Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1 (2024)
    Experimental Biology and Medicine 4 citations DOI OpenAlex
  • Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing (2024)
    Scientific Data 9 citations DOI OpenAlex
  • Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA Labeling (2024)
    Drug Safety 9 citations DOI OpenAlex
  • Assessing the performance of large language models in literature screening for pharmacovigilance: a comparative study (2024)
    Frontiers in Drug Safety and Regulation 16 citations DOI OpenAlex
  • Automatic text classification of drug-induced liver injury using document-term matrix and XGBoost (2024)
    Frontiers in Artificial Intelligence 6 citations DOI OpenAlex
  • PERform: assessing model performance with predictivity and explainability readiness formula (2024)
    Journal of Environmental Science and Health Part C 2 citations DOI OpenAlex
  • Towards accurate indel calling for oncopanel sequencing through an international pipeline competition at precisionFDA (2024)
    Scientific Reports 3 citations DOI OpenAlex
  • A framework enabling LLMs into regulatory environment for transparency and trustworthiness and its application to drug labeling document (2024)
    Regulatory Toxicology and Pharmacology 13 citations DOI OpenAlex
  • Extend the benchmarking indel set by manual review using the individual cell line sequencing data from the Sequencing Quality Control 2 (SEQC2) project (2024)
    Scientific Reports 5 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

290 Collaborators 108 Institutions 16 Countries

Top Collaborators

View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics